헤더 로고

• All Rooms
• Galaxy Theater & Discovery Hall
• Galaxy Theater
• Discovery Hall
• Universe Arena
• Supernova Stage
• Grand 4+5

March 26 (Thursday)

[OP01] Oral Presentation 01: Acute Leukemia-1 Galaxy Theater

• March 26 (Thu), 13:55-15:10
• Jae Wook Lee (College of Medicine, The Catholic University of Korea, Korea)
  Joon Ho Moon (Kyungpook National University School of Medicine, Korea)
• 13:55-14:07 Development and Internal Validation of a Simple Three-Gene Risk Score for Elderly AML Patients Receiving Nonintensive Therapy Sang-A Kim (Seoul National University College of Medicine, Korea) 14:07-14:19 The Impact of RUNX1-RUNX1T1 Transcript Kinetics and Co-Mutation on the Post-Transplant Outcomes in Acute Myeloid Leukemia with T(8;21): A Real-World Study Yi Xia (Peking University People’s Hospital, China) 14:19-14:31 Prognostic Heterogeneity and Treatment Outcomes in TP53 Mutated Acute Myeloid Leukemia : A Prospective Nationwide Multicenter Study Mihee Kim (Chonnam National University Hwasun Hospital, Korea) 14:31-14:43 Comprehensive Prognostic Stratification by Gene Deletion Profiles in Adult patients with BCP-ALL: Distinct Biological and Clinical Implications in Ph-Negative and Ph-Positive ALL Jae-Ho Yoon (College of Medicine, The Catholic University of Korea, Korea) 14:43-14:55 Revealing Subtype-Specific Immunophenotypic and Cytogenetic Patterns That Improve Detection of Measurable Residual Disease in B-Lymphoblastic Leukemia Ju Hyeong Lee (Seoul National University Hospital, Korea) 14:55-15:07 Impact of End-of-Induction Measurable Residual Disease Status Across Cytogenetic Subtypes Among Pediatric Patients With B-Lineage Acute Lymphoblastic Leukemia: Do TCF3::PBX1 Patients Warrant Altered Risk Stratification and Treatment? Karthik Bommannan Bommannan Kuppuraju (Cancer Institute (W.I.A), India)

[OP02] Oral Presentation 02: Myelodysplastic Syndrome & Myeloproliferative Neoplasm Discovery Hall

• March 26 (Thu), 13:55-15:10
• Dong-Yeop Shin (Seoul National University College of Medicine, Korea)
  Sung-Eun Lee (College of Medicine, The Catholic University of Korea, Korea)
• 13:55-14:07 ASXL1 Mutation Status Influences the Response to Retinoid-Based Epigenetic Differentiation Therapy in MDS/AML Lukasz Szymanski (Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, Poland) 14:07-14:19 TP53 Allelic State Defines Infection Susceptibility in Myelodysplastic Syndrome and Acute Myeloid Leukemia Junshik Hong (Seoul National University Hospital, Korea) 14:19-14:31 Therapy-Related Myelodysplastic Syndromes: Clinical Characteristics and Real-World Treatment Outcomes from a Single-Center Cohort Yunsuk Choi (Asan Medical Center, Korea) 14:31-14:43 Individualized Decitabine Dosing for Post-HSCT Maintenance in MDS: Long-Term Outcomes from the PODAC Trial and Matched Controls Hohyung Nam (Seoul St. Mary's Hospital, Korea) 14:43-14:55 Ropeginterferon Dose-Escalation Strategies in PV: A Systematic Review and Meta-Analysis Seug Yun Yoon (Soonchunhyang University Seoul Hospital, Korea) 14:55-15:07 Long-term Molecular Response to Ropeginterferon alfa-2b and Clinical Validation of qPCR for Low-Level JAK2 Monitoring in Polycythemia Vera So Yeon Park (Seoul St. Mary's Hospital, Korea)

[OP03] Oral Presentation 03: Lymphoma Universe Arena

• March 26 (Thu), 13:55-15:10
• Young Hoon Park (Ewha Womans University College of Medicine, Korea)
  TBD
• 13:55-14:07 Phase II Study of Lenalidomide Maintenance after Rituximab-Methotrexate-Based Induction Therapy in Primary CNS Lymphoma Ji Yun Lee (Seoul National University Bundang Hospital, Korea) 14:07-14:19 Phase 1 Study of GCC2005, an Allogeneic CD5-Directed CAR-NK Therapy, for Patients with Relapsed/Refractory NK/T-Cell Malignancies Dok Hyun Yoon (University of Ulsan College of Medicine, Korea) 14:19-14:31 Treatment Patterns and Survival Outcomes in Patients with Mantle Cell Lymphoma: Updated Interim Report of the Asia-Pacific Multinational Prospective Registry Study Hyungwoo Cho (University of Ulsan College of Medicine, Korea) 14:31-14:43 Clinical and Functional Impact of CD19-Positive Extracellular Vesicles in CD19 CAR-T Treated Diffuse Large B-Cell Lymphoma Bon Park (Sungkyunkwan University, Korea) 14:43-14:55 Longitudinal Whole Exome Sequencing Identifies Clonal Hematopoiesis and Genomic Heterogeneity as Predictors of Treatment Outcome in Newly Diagnosed Chronic Lymphocytic Leukemia Treated with Chlorambucil-Obinutuzumab Ho Cheol Jang (Chonnam National University Hwasun Hospital, Korea) 14:55-15:07 The Role of Maintenance Therapy with PD-1 Inhibitors after Autologous HSCT in Patients with Classical Hodgkin Lymphoma at High Risk of Relapse and Progression Ekaterina Fastova (National Medical Research Center for Hematology, Russia)

[OP04] Oral Presentation 04: General Hematology Supernova Stage

• March 26 (Thu), 13:55-15:10
• Sung Hwa Bae (Daegu Catholic University School of Medicine, Korea)
  Yoon Hwan Chang (Seoul National University College of Medicine, Korea)
• 13:55-14:07 Long-Term Outcomes and Inhibitor Relapse Following Immune Tolerance Induction in Severe Hemophilia a Patients with Inhibitors: A Prospective Multicenter Study Zhengping Li (Beijing Children's Hospital, Capital Medical University, China) 14:07-14:19 A Reference Laboratory’s Experience with 16 Unstable Hemoglobin Variants over 14 Years: Diagnostic Clues, Pitfalls, and the Role of Sequencing Prashant Sharma (Postgraduate Institute of Medical Education and Research, India) 14:19-14:31 Efficacy of HLA-Matched Platelet Transfusion and Its Predictors in Platelet Refractory Patients with Hematologic Malignancies Jiwoo Lee (Seoul National University Hospital, Korea) 14:31-14:43 Impact of Anti-CD38 Monoclonal Antibody Therapy on Pretransfusion Testing and Transfusion Strategies in Multiple Myeloma Patients at an Eastern Taiwan Medical Center Min-Hsuan Lan (Tzu Chi University, Tzu Chi Hospital, Taiwan) 14:43-14:55 Artificial Intelligence-Optimized Monocytosis Workflow: Transforming Early Detection of Hematologic Malignancies in Automated Hematology Systems Yama Sirly Putri (Faculty of Medicine Indo Global Mandiri University, Indonesia) 14:55-15:07 Clinical Effectiveness and Bleeding Outcomes of Edoxaban for Cancer-Associated Venous Thromboembolism in Korean Patients: A Prospective, Multicenter, Single-Arm, Observational Cohort Study Ho-Young Yhim (Jeonbuk National University Medical School, Korea)

March 27 (Friday)

[OP05] Oral Presentation 05: Acute Leukemia-2 Galaxy Theater

• March 27 (Fri), 13:35-14:50
• Yong Park (Korea University College of Medicine)
  TBD
• 13:35-13:47 Development of Preclinical Leukemic Models for Acquired Resistance to a FLT3 Inhibitor Eun-Ji Choi (Asan Medical Center, Korea) 13:47-13:59 The Effect of Allogeneic HSCT on Pediatric nonDown Syndrome AMKL: Results from a Multicenter CALD-AMKL-18 Trial Shengqin Cheng (Children's Hospital of Soochow University, China) 13:59:14:11 Clinical Characteristics and Prognostic Implications according to Partner Genes in Adult Acute Myeloid Leukemia with KMT2A Rearrangement So Yeon Park (Seoul St. Mary's Hospital, Korea) 14:11-14:23 Combinatorial Cell-Surface Markers Derived from Single-Cell Transcriptomics Enable Precise Discrimination of LSCs from HSCs in Acute Myeloid Leukemia Smeeta Gajendra (All India Institute of Medical Sciences, India) 14:23-14:35 Refining Genomic Risk Stratification in Adult Patients with Ph-Negative All by Functional Classification of Ikzf1 Deletions Seung-Hwan Lee (Seoul St. Mary’s Hospital, Korea) 14:35-14:47 Immunotargeted Therapy Challenges the Role of Second Transplantation after Post-Transplant Relapse in Adult Patients with B-ALL : A Contemporary Real-World Analysis Jaehyun Ahn (Seoul St. Mary’s Hospital, Korea)

[OP06] Oral Presentation 06: Hematopoietic Stem Cell Transplantation / Cellular Therapy Discovery Hall

• March 27 (Fri), 13:35-14:50
• Byung Su Kim (College of Medicine, The Catholic University of Korea, Korea)
  TBD
• 13:35-13:47 Clinical Benefits of Ruxolitinib in Moderate-to-Severe CRS: Reduced Severe ICANS and Steroid Use With Preserved Survival after Pediatric CAR-T Therapy Qi Ji (Children’s Hospital of Soochow University, Jiangsu Province, China) 13:47-13:59 CD19 CAR-T Therapy for Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL): the First Investigator-Initiated Trial with Point-of-Care CAR-T Manufacturing in Korea Hyoung Jin Kang (Seoul Natinal University College of Medicine, Korea) 13:59:14:11 Post-Autologous Stem Cell Transplantation Cytokine-Induced Killer Cell Infusion as a Post-Remission Strategy in High-Risk Lymphoma Gi June Min (Seoul St. Mary’s Hospital, Korea) 14:11-14:23 Reduced-Intensity Conditioning Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Severe Aplastic Anemia: A Single-Center Study Hyun Jin Park (Seoul National University College of Medicine, Korea) 14:23-14:35 Vedolizumab for Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: A Real-World VAST Study Yi Xia (Peking University People’s Hospital, China) 14:35-14:47 Distinct Dynamics of Regulatory T cells after Allogeneic Hematopoietic Cell Transplantation Using Post-transplantation Cyclophosphamide vs. Antithymocyte Globulin Eun-Ji Choi (Asan Medical Center, Korea)

[OP07] Oral Presentation 07: Multiple Myeloma Universe Arena

• March 27 (Fri), 13:35-14:50
• Min Kyoung Kim (Yeungnam University College of Medicine, Korea)
  TBD
• 13:35-13:47 Prevalence and Prognostic Impact of 1p32 Deletion in Newly Diagnosed Multiple Myeloma Sreejesh Sreedharanunni (Postgraduate Institute of Medical Education and Research, India) 13:47-13:59 Single Cell Transcriptomic Profiling of Bone Marrow Reveals Progressive T Cell Exhaustion and Myeloid Activation in Multiple Myeloma and Plasma Cell Leukemia Ho Cheol Jang (Chonnam National University Hwasun Hospital, Korea) 13:59:14:11 Deep Hematologic Response Overrides the Impact of Treatment Modality on Progression-Free Survival in AL Amyloidosis: A Korean Multicenter Study Joon Young Hur (Asan Medical Center, Korea) 14:11-14:23 Mezigdomide Enhances BCMAxCD3 T-Cell Engager-Induced Cytotoxicity Under High Target Cell Load Conditions Hyunsoo Cho (Seoul National University Hospital, Korea) 14:23-14:35 Prospective, Multicenter Phase II Study to Evaluate Clinical Benefit of Reduced-Dose Lenalidomide and Dexamethasone based on Frailty Stratification in Elderly Unfit Patients with Newly Diagnosed Multiple Myeloma Sung-Hoon Jung (Chonnam National University Medical School, Korea) 14:35-14:47 Decoding the Role of TANGO1 in Myeloma Proteostasis and Therapeutic Vulnerability Ji Eun Lee (Yonsei University College of Medicine, Korea)

[OP08] Oral Presentation 08: Cytopenia & Bone Marrow Failure Supernova Stage

• March 27 (Fri), 13:35-14:50
• Yeon Jung Lim (Chungnam National University College of Medicine, Korea)
  TBD
• 13:35-13:47 Diagnostic Errors of Beta-Thalassemia by Hemoglobin Variants with Elevated Hb A2 Levels and Co-Migration with Hb F Kritsada Singha (Khon Kaen University, Mahasarakham University, Thailand) 13:47-13:59 Expanding Genetic Landscape of Inherited Bone Marrow Failure Syndromes: Insights from the Canadian Inherited Marrow Failure Registry (CIMFR) (2001-2023) Ye Jee Shim (Kyungpook National University Children's Hospital, Korea) 13:59:14:11 Integrative Transcriptomic Profiling Reveals Shared mRNA and lncRNA Signatures in Pediatric Bone Marrow Failure Syndromes Jong-Mi Lee (Seoul St. Mary’s Hospital, Korea) 14:11-14:23 Umbilical Cord Blood Transplantation for Primary Immunodeficiency in Children: A Ten-Year Single-Center Clinical Analysis Qingwei Wang (Children's Hospital of Soochow University, Jiangsu Provincial Center for Pediatric Hematology and Oncology, China) 14:23-14:35 First-line Hetrombopag Combined with Immunosuppressive Therapy for Pediatric Severe Aplastic Anemia: A Prospective Randomized Controlled Trial Lingling Fu (Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, China) 14:35-14:47 Emergency Myelopoiesis and Monocyte Reprogramming Underlie Immune Dysregulation in Lymphoma-Associated Secondary Hemophagocytic Lymphohistiocytosis Jeong-Eun Kwak (Seoul National University Hospital, Korea)